Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $130.13M | $77.43M | $23.64M | $3.15M | N/A | N/A | N/A | N/A |
| Cost of Revenue | $13.37M | $9.30M | $2.13M | $599.00K | $690.00K | $834.00K | $442.00K | $223.00K |
| Gross Profit | $116.76M | $68.13M | $21.50M | $2.56M | $-690.00K | $-834.00K | $-442.00K | $-223.00K |
| Gross Margin | 89.73% | 87.99% | 90.98% | 81.01% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Expenses | $382.26M | $252.48M | $200.66M | $172.61M | $135.88M | $145.17M | $77.97M | $32.19M |
| Operating Income | $-265.50M | $-184.36M | $-179.16M | $-170.06M | $-136.57M | $-146.00M | $-78.42M | $-32.41M |
| Operating Margin | -204.04% | -238.10% | -757.92% | -5391.85% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income | $-260.60M | $-184.68M | $-181.12M | $-69.61M | $-130.73M | $-134.62M | $-74.06M | $-33.71M |
| Net Margin | -200.27% | -238.52% | -766.22% | -2207.10% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS (Basic) | $-4.34 | $-3.20 | $-3.51 | $-1.37 | $-2.96 | $-3.70 | $-2.39 | $-1.26 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |